Single domain antibodies capable of modulating BACE activity
AssigneesVib Vzw, Katholieke Universiteit Leuven, KU LEUVEN R&D, Vrije Universiteit Brussel
InventorsBart De Strooper, Els Marjaux, Lujia Zhou, Serge Muyldermans
Life of this patent
Estimating the term…
Abstract
Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.
Claims9
A single domain antibody, devoid of a light chain, that specifically binds beta secretase (BACE1) and inhibits BACE1 activity, wherein the single domain antibody comprises three complementarity determining regions (CDRs) comprising the amino acid sequences of SEQ ID NOS:
- 29, 30, and 31.
Dependencies are inferred from the claim text.